Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$22.65 +0.4%	$21.51	$16.50 ▼ $26.50	$1.97B	N/A	65,552 shs	4,835 shs
BHVN Biohaven	$16.07 +1.6%	$22.31	$14.69 ▼ $55.70	$1.64B	1.18	1.21 million shs	3.84 million shs
KURA Kura Oncology	$6.02 +1.2%	$6.42	$5.41 ▼ $23.48	$521.18M	0.5	1.18 million shs	1.07 million shs
KYMR Kymera Therapeutics	$30.25 +0.8%	$29.36	$19.45 ▼ $53.27	$1.97B	2.18	561,963 shs	440,383 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.40%	-6.83%	+20.03%	+24.18%	+2,264,999,900.00%
BHVN Biohaven	+1.64%	-20.45%	-14.20%	-61.23%	-56.66%
KURA Kura Oncology	+1.18%	+4.33%	+4.70%	-27.29%	-72.47%
KYMR Kymera Therapeutics	+0.77%	+0.60%	+20.90%	-17.98%	-15.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	3.6789 of 5 stars	4.6	1.0	0.0	0.0	3.2	4.2	0.6
KURA Kura Oncology	4.3939 of 5 stars	4.5	2.0	0.0	4.7	3.6	0.0	0.6
KYMR Kymera Therapeutics	2.726 of 5 stars	4.4	2.0	0.0	0.0	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
BHVN Biohaven	3.13	Buy	$62.00	285.81% Upside
KURA Kura Oncology	2.92	Moderate Buy	$23.89	296.83% Upside
KYMR Kymera Therapeutics	2.81	Moderate Buy	$55.27	82.70% Upside

Current Analyst Ratings Breakdown

Latest KURA, AAPG, KYMR, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	BHVN Biohaven	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$61.00 ➝ $54.00
5/13/2025	KYMR Kymera Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$72.00 ➝ $70.00
5/12/2025	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$47.00 ➝ $44.00
5/12/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
4/29/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00 ➝ $28.00
4/28/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $57.00
4/28/2025	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/24/2025	BHVN Biohaven	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00

(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	2.01	N/A	N/A	N/A	∞
BHVN Biohaven	N/A	N/A	N/A	N/A	$5.34 per share	N/A
KURA Kura Oncology	$67.99M	7.67	N/A	N/A	$5.35 per share	1.13
KYMR Kymera Therapeutics	$58.89M	33.45	N/A	N/A	$7.12 per share	4.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	-$408.17M	-$9.39	N/A	N/A	N/A	N/A	-225.12%	-158.89%	N/A
KURA Kura Oncology	-$152.63M	-$2.10	N/A	N/A	N/A	N/A	-44.09%	-39.57%	N/A
KYMR Kymera Therapeutics	-$146.96M	-$3.10	N/A	N/A	N/A	-191.26%	-24.96%	-20.27%	N/A

Latest KURA, AAPG, KYMR, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million
3/3/2025	Q4 2024	BHVN Biohaven	-$1.56	-$1.85	-$0.29	-$1.85	$100.00 million	N/A
2/27/2025	Q4 2024	KYMR Kymera Therapeutics	-$0.76	-$0.88	-$0.12	-$0.88	$14.81 million	$7.39 million
2/26/2025	Q4 2024	KURA Kura Oncology	-$0.65	-$0.22	+$0.43	-$0.22	$57.96 million	$53.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	N/A	N/A	N/A
BHVN Biohaven	N/A	2.89	2.89
KURA Kura Oncology	0.02	11.47	11.47
KYMR Kymera Therapeutics	N/A	8.55	8.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
BHVN Biohaven	88.78%
KURA Kura Oncology	N/A
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
BHVN Biohaven	16.00%
KURA Kura Oncology	6.40%
KYMR Kymera Therapeutics	16.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.07 million	N/A	N/A
BHVN Biohaven	239	102.07 million	84.94 million	Optionable
KURA Kura Oncology	130	86.58 million	73.49 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.52 million	Optionable

KURA, AAPG, KYMR, and BHVN Headlines

Recent News About These Companies

Northern Trust Corp Has $17.61 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

May 17 at 3:44 AM | marketbeat.com

HC Wainwright Issues Optimistic Estimate for KYMR Earnings

May 17 at 2:41 AM | americanbankingnews.com

B. Riley Lifts Earnings Estimates for Kymera Therapeutics

May 16 at 6:03 AM | marketbeat.com

Comerica Bank Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

May 16 at 3:55 AM | marketbeat.com

Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst

May 15 at 1:01 AM | americanbankingnews.com

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts

May 14 at 10:41 PM | nasdaq.com

Which Is a Better Investment, Kymera Therapeutics, Inc. or Moderna, Inc. Stock?

May 14 at 10:41 PM | aaii.com

Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff

May 14 at 5:11 PM | seekingalpha.com

Bank of America Issues Pessimistic Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

May 14 at 10:50 AM | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from Guggenheim

May 14 at 10:50 AM | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Earns "Buy" Rating from Guggenheim

May 14 at 2:11 AM | americanbankingnews.com

Bank of America Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

May 14 at 2:11 AM | americanbankingnews.com

Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

May 13, 2025 | marketbeat.com

Why Kymera Therapeutics, Inc.’s (KYMR) Stock Is Up 11.54%

May 12, 2025 | aaii.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Frontier Capital Management Co. LLC

May 12, 2025 | marketbeat.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Deerfield Management Company L.P. Series C Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

May 10, 2025 | marketbeat.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stake Boosted by Driehaus Capital Management LLC

May 10, 2025 | marketbeat.com

The Manufacturers Life Insurance Company Grows Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

May 10, 2025 | marketbeat.com

Dimensional Fund Advisors LP Sells 38,871 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

May 10, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Earnings Beat

May 10, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, AAPG, KYMR, and BHVN Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$22.65 +0.09 (+0.40%)

As of 05/16/2025 03:09 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Biohaven NYSE:BHVN

$16.07 +0.25 (+1.58%)

Closing price 05/16/2025 03:59 PM Eastern

Extended Trading

$15.96 -0.11 (-0.68%)

As of 05/16/2025 07:17 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Kura Oncology NASDAQ:KURA

$6.02 +0.07 (+1.18%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$5.91 -0.11 (-1.83%)

As of 05/16/2025 06:22 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Kymera Therapeutics NASDAQ:KYMR

$30.25 +0.23 (+0.77%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$28.25 -2.00 (-6.61%)

As of 05/16/2025 07:56 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time